The Pharmacotherapies for Alcohol and Substance Use Disorder Alliance (PASA) is funded by the Congressionally Directed Medical Research Programs (CDMRP) as part of its Alcohol and Substance Use Disorders Research Program (ASUDRP) consortium awards (W81XWH-17-ASADRP-CA and W81XWH-21-ASADRP-CA).

The PASA’s goal is to fund studies that explore integrated approaches to address ASUD, especially comorbid ASUD with Post-Traumatic Stress Disorder (PTSD) and other psychological disorders, and reduce the number of opioid and other substance use-related deaths through multidisciplinary, team-based research efforts that translate basic knowledge into enhanced clinical pharmacological treatment protocols and enhanced quality of life for Service Members, Veterans, and the American public. Studies of military and Veteran populations are encouraged. These medications will ideally address the comorbidity between ASUDs and PTSD or other psychological disorders, as these comorbidities are common in the military and Veteran populations. Commercialization linked to U.S. Food and Drug Administration approval for these new medications or combinations of medications is critical, so early linkages to pharmaceutical companies are considered strengths of any application for PASA funding.

The PASA is offering four Research Mechanisms:

1.     RFA 7a/Planning Award - Period of Performance is 9-12 months, with a maximum Total Cost (indirect and direct) of $150,000.

2.    RFA 7b/Pre-Clinical Award - Period of Performance is 18 months, with a maximum Total Cost (indirect and direct) of $600,000.

3.    RFA 7c/Non-Clinical Award - Period of Performance is 24 months, with a maximum Total Cost (indirect and direct) of $600,000.

4.    RFA 7d/Expansion Award - Period of Performance is 12-24 months, with a maximum Total Cost (indirect and direct) of $250,000 to $750,000.

Read more details about these awards